AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile

AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile
Published Oct 18, 2016
41 pages — Published Oct 18, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

AcelRx Pharmaceuticals, Inc. (AcelRx), formerly SuRx, Inc., focuses on the development and commercialization of novel therapies for the treatment of acute pain. Its pipeline product portfolio includes ARX-04 and Zalviso. AcelRxs ARX-04 is used as non-invasive treatment option for the patients with moderate-to-severe acute pain; Zalviso, a device designed to manage the moderate to severe acute pain in adults and ARX-03, used to treat the mild sedation and pain relief. It utilizes its sublingual formulation technology to develop lipophilic drugs with the consistent pharmacokinetic profiles. The company offers zalviso to the customers across European Union.

AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical Equipment eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information

  
Source:
Document ID
GDME26475D
Country
Industry
Ticker
ACRX=US
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
AcelRx Pharmaceuticals, Inc., Medical Equipment, Deals By Year, 2010 to YTD 201652
AcelRx Pharmaceuticals, Inc., Medical Equipment Deals By Type, 2010 to YTD 201671
AcelRx Pharmaceuticals, Inc., Medical Equipment, Deals By Region, 2010 to YTD 201681
AcelRx Pharmaceuticals, Inc., Medical Equipment, Deals By Market, 2010 to YTD 201691
AcelRx Pharmaceuticals, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016101
AcelRx Pharmaceuticals, Inc., Medical Equipment, Deal Details1111
  Venture Financing111
    AcelRx Pharma Raises US$8 Million In Venture Financing111
  Partnerships121
    AcelRx Pharma Amends Commercialization Agreement With Grunenthal For Zalviso121
  Equity Offering131
    AcelRx Pharma Completes Public Offering Of Shares For US$51 Million132
    AcelRx Pharma Completes Underwriters' Exercise Of Over-Allotment Option For US$6 Million152
    AcelRx Pharma Completes Private Placement Of Units For US$10 Million171
    AcelRx Pharma Completes IPO Of US$40 Million182
  Asset Transactions201
    PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million202
AcelRx Pharmaceuticals, Inc. - Key Competitors221
Key Employees231
Locations And Subsidiaries241
  Head Office241
  Other Locations &Subsidiaries241
Recent Developments251
Financial Announcements251
Jul 28, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Second Quarter and Six Months 2016 Financial Results253
Mar 07, 2016: AcelRx Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full Year 2015 Financial Results282
Oct 29, 2015: AcelRx Pharmaceuticals Provides Business Update and Reports Third Quarter and Nine Months 2015 Financial Results302
Aug 03, 2015: AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results322
May 04, 2015: AcelRx Pharmaceuticals Reports First Quarter 2015 Financial Results341
Mar 09, 2015: AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial Results351
Corporate Communications361
Mar 29, 2016: AcelRx Pharmaceuticals Names Howard B. Rosen as Chief Executive Officer and Provides Update on Clinical Development Activities and Corporate Priorities for 2016361
Oct 01, 2015: AcelRx Pharmaceuticals Appoints Gina Ford as Vice President Commercial Strategy371
Mar 20, 2015: AcelRx Appoints Howard B. Rosen as Interim CEO381
Product News391
Sep 22, 2015: AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients391
Product Approvals401
Sep 22, 2015: AcelRx Pharmaceuticals Reports that the European Commission has Granted Marketing Authorization for Zalviso for Treatment of Acute Moderate-to-Severe Post-Operative Pain in Adult Patients401
Appendix411
  Methodology411
  About GlobalData411
  Contact Us411
  Disclaimer411

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile" Oct 18, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/AcelRx-Pharmaceuticals-Inc-ACRX-Medical-Equipment-Deals-and-Alliances-Profile-2148-3773>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). AcelRx Pharmaceuticals, Inc. (ACRX) - Medical Equipment - Deals and Alliances Profile Oct 18, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/AcelRx-Pharmaceuticals-Inc-ACRX-Medical-Equipment-Deals-and-Alliances-Profile-2148-3773>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research